Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: Uptake and timing

Clinical Genetics

Volumn 77, Issue 4, 2010, Pages 342-349

  Skytte, A B ^a   Gerdes, A M ^b   Andersen, M K ^c   Sunde, L ^d   Brondum Nielsen K ^e   Waldstrom M ^a   Kolvraa S ^a   Cruger D ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Kennedy Centre   (Denmark)

Author keywords

BRCA1; BRCA2; Mastectomy; Risk reducing; Salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CHILDBIRTH; CONTROLLED STUDY; DENMARK; FEMALE; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MUTATIONAL ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; FALLOPIAN TUBES; FEMALE; HETEROZYGOTE; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIECTOMY; RISK FACTORS; TIME FACTORS;

EID: 77951704364     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01329.x     Document Type: Article

References (37)

1. Antoniou AC, Cunningham AP, Peto J. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008, 98:1457-1466.
2. Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333.
4. Marroni F, Aretini P, D'Andrea E. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004, 12(11):899-906.
5. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62(3):676-689. The Breast Cancer Linkage Consortium
6. Easton DF, Bishop DT, Ford D. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993, 52(4):678-701. The Breast Cancer Linkage Consortium
7. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007, 96(1):11-15.
8. Gronwald J, Huzarski T, Byrski B. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet 2006, 43(5):424-428.
9. Finch A, Beiner M, Lubinski J. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296(2):185-192.
10. Uyei A, Peterson SK, Erlichman J. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 2006, 107(12):2745-2751.
11. Ray JA, Loescher LJ, Brewer M. Risk-reduction surgery decisions in high-risk women seen for genetic counseling. J Genet Couns 2005, 14(6):473-484.
12. Rebbeck TR, Lynch HT, Neuhausen SL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346(21):1616-1622.
13. Kauff ND, Domchek SM, Friebel TM. Risk-reducing salpingo-oophorectomy for the prevention of. B J Clin Oncol 2008, 26:1331-1337.
14. Eisen A, Lubinski J, Klijn J. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23(30):7491-7496.
15. Rebbeck TR, Levin AM, Eisen A. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91(17):1475-1479.
16. Domchek SM, Friebel TM, Neuhausen SL. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006, 7(3):223-229.
17. Rebbeck TR, Friebel T, Lynch HT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004, 22(6):1055-1062.
18. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol 2007, 14(12):3335-3344.
19. Hartmann LC, Sellers TA, Schaid DJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93(21):1633-1637.
20. Meijers-Heijboer H, van Geel B, van Putten WL. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345(3):159-164.
21. Woodward ER, Sleightholme HV, Considine AM. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 2007, 114(12):1500-1509.
22. Oei AL, Massuger LF, Bulten J. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006, 94(6):814-819.
23. Evans GR, Gaarenstroom KN, Stirling D. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009, 46:593-597.
24. Sardanelli F, Podo F, D'Agnolo G. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007, 242(3):698-715.
25. Trecate G, Vergnaghi D, Manoukian S. MRI in the early detection of breast cancer in women with high genetic risk. Tumori 2006, 92(6):517-523.
26. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br J Radiol 2008, 81(963):172-179.
27. Moller P, Evans DG, Reis MM. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 2007, 121(5):1017-1020.
28. Metcalfe KA, Liede A, Hoodfar E. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet 2000, 37(11):866-874.
29. Lodder LN, Frets PG, Trijsburg RW. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002, 73(2):97-112.
30. Wagner TM, Moslinger R, Langbauer G. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000, 82(7):1249-1253.
31. Lerman C, Hughes C, Croyle RT. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000, 31(1):75-80.
32. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000, 355(9220):2015-2020.
33. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122:2017-2022.
34. Bradbury AR, Ibe CN, Dignam JJ. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med 2008, 10(3):161-166.
35. Phillips KA, Jenkins MA, Lindeman GJ. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006, 70(3):198-206.
36. Friebel TM, Domchek SM, Neuhausen SL. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 2007, 7(11):875-882.
37. Ackermann S, Lux MP, Fasching PA. Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. Eur J Cancer Prev 2006, 15(6):474-479.